Clinical Trial: Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma

U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07891923) titled 'Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma' on July 11.

Brief Summary: The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when added to standard VRd therapy, can be an effective induction regimen for treating newly diagnosed multiple myeloma (NDMM).

The main questions it aims to answer are:

1. Does the modified (less frequent) daratumumab dosing regimen increase the rate of MRD (minimal residual disease) negativity after 4 cycles of induction therapy (as compared to standard VRd therapy)?

2. Is the modified less-freq...